Last reviewed · How we verify

L-ARG+GHRH — Competitive Intelligence Brief

L-ARG+GHRH (L-ARG+GHRH) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth hormone secretagogue / amino acid combination. Area: Endocrinology / Metabolic disorders.

phase 3 Growth hormone secretagogue / amino acid combination GHRH receptor (GHRHR); nitric oxide pathway Endocrinology / Metabolic disorders Small molecule Live · refreshed every 30 min

Target snapshot

L-ARG+GHRH (L-ARG+GHRH) — AEterna Zentaris. L-arginine combined with growth hormone-releasing hormone (GHRH) stimulates endogenous growth hormone secretion to promote anabolic effects and tissue repair.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
L-ARG+GHRH TARGET L-ARG+GHRH AEterna Zentaris phase 3 Growth hormone secretagogue / amino acid combination GHRH receptor (GHRHR); nitric oxide pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth hormone secretagogue / amino acid combination class)

  1. AEterna Zentaris · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). L-ARG+GHRH — Competitive Intelligence Brief. https://druglandscape.com/ci/l-arg-ghrh. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: